The developer of Russia's Sputnik V coronavirus vaccine said Friday it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab. The Russian Direct Investment Fund (RDIF), which backed the development of Sputnik V, said in a statement it had partnered with Stelis Biopharma "to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine". acl/emg/lc